Brian A Darlow1, Kei Lui2, Satoshi Kusuda3, Brian Reichman4, Stellan Håkansson5, Dirk Bassler6, Neena Modi7, Shoo K Lee8,9, Liisa Lehtonen10, Maximo Vento11, Tetsuya Isayama8, Gunnar Sjörs12, Kjell K Helenius10, Mark Adams6, Franca Rusconi13,14, Naho Morisaki15, Prakesh S Shah8,9. 1. Australia and New Zealand Neonatal Network, Department of Paediatrics, University of Otago, Christchurch, New Zealand. 2. Australian and New Zealand Neonatal Network, Royal Hospital for Women, National Perinatal Epidemiology and Statistic Unit, University of New South Wales, Randwick, Australia. 3. Neonatal Research Network Japan, Maternal and Perinatal Center, Tokyo Women's Medical University, Kawadacho, Shinjuku, Tokyo, Japan. 4. Israel Neonatal Network, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Centre, Tel Hashomer, Israel. 5. Swedish Neonatal Quality Register, Department of Pediatrics/Neonatal Services, Umeå University Hospital, Umeå, Sweden. 6. Swiss Neonatal Network, Department of Neonatology, University Hospital Zurich, University of Zurich, Frauenklinikstrasse, Zurich, Switzerland. 7. UK Neonatal Collaborative, Neonatal Data Analysis Unit, Section of Neonatal Medicine, Department of Medicine, Imperial College London, Chelsea and Westminster Hospital campus, London, UK. 8. Department of Paediatrics, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada. 9. Canadian Neonatal Network, Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, Ontario, Canada. 10. Finnish Medical Birth Register and Register of Congenital Malformations, Department of Pediatrics, Turku Univeristy Hospital, Kiinamyllynkatu, Turku, Finland. 11. Spanish Neonatal Network, Health Research Institute La Fe, Avenida Fernando Abril Martorell, Valencia, Spain. 12. Swedish Neonatal Quality Register, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. 13. TIN Toscane Online, Unit of Epidemiology, Meyer Children's University Hospital, Viale Pieraccini, Florence, Italy. 14. Regional Health Agency, Via Pietro Dazzi, Florence, Italy. 15. Neonatal Research Network Japan, Department of Social Medicine, National Center for Child Health and Development, Okura, Setagaya, Tokyo, Japan.
Abstract
OBJECTIVE: To compare the rates of retinopathy of prematurity (ROP) and treatment of ROP by laser or intravitreal anti-vascular endothelial growth factor among preterm neonates from high-income countries participating in the International Network for Evaluating Outcomes (iNeo) of neonates. METHODS: A retrospective cohort study was conducted on extremely preterm infants weighing <1500 g at 240 to 276 weeks' gestation who were admitted to neonatal units in Australia/New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK between 2007 and 2013. Pairwise comparisons of ROP treatment in survivors between countries were evaluated by Poisson and multivariable logistic regression analyses after adjustment for confounders. A composite outcome of death or ROP treatment was compared between countries using logistic regression and standardised ratios. RESULTS: Of 48 087 infants included in the analysis, 81.8% survived to 32 weeks postmenstrual age, and 95% of survivors were screened for ROP. Rates of any ROP ranged from 25.2% to 91.0% in Switzerland and Japan, respectively, among those examined. The overall rate of those receiving treatment was 24.9%, which varied from 4.3% to 30.4%. Adjusted risk ratios for ROP treatment were lower for Switzerland in all pairwise comparisons, whereas Japan displayed significantly higher ratios. Comparisons of the composite outcome between countries revealed similar, but less marked differences. CONCLUSIONS: Rates of any ROP and ROP treatment varied significantly between iNeo members, while an overall decline in ROP treatment was observed during the study period. It is unclear whether these variations represent differences in care practices, diagnosis and/or treatment thresholds. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To compare the rates of retinopathy of prematurity (ROP) and treatment of ROP by laser or intravitreal anti-vascular endothelial growth factor among preterm neonates from high-income countries participating in the International Network for Evaluating Outcomes (iNeo) of neonates. METHODS: A retrospective cohort study was conducted on extremely preterm infants weighing <1500 g at 240 to 276 weeks' gestation who were admitted to neonatal units in Australia/New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK between 2007 and 2013. Pairwise comparisons of ROP treatment in survivors between countries were evaluated by Poisson and multivariable logistic regression analyses after adjustment for confounders. A composite outcome of death or ROP treatment was compared between countries using logistic regression and standardised ratios. RESULTS: Of 48 087 infants included in the analysis, 81.8% survived to 32 weeks postmenstrual age, and 95% of survivors were screened for ROP. Rates of any ROP ranged from 25.2% to 91.0% in Switzerland and Japan, respectively, among those examined. The overall rate of those receiving treatment was 24.9%, which varied from 4.3% to 30.4%. Adjusted risk ratios for ROP treatment were lower for Switzerland in all pairwise comparisons, whereas Japan displayed significantly higher ratios. Comparisons of the composite outcome between countries revealed similar, but less marked differences. CONCLUSIONS: Rates of any ROP and ROP treatment varied significantly between iNeo members, while an overall decline in ROP treatment was observed during the study period. It is unclear whether these variations represent differences in care practices, diagnosis and/or treatment thresholds. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Child health (paediatrics); Epidemiology; Retina
Authors: Prakesh S Shah; Kei Lui; Brian Reichman; Mikael Norman; Satoshi Kusuda; Liisa Lehtonen; Mark Adams; Maximo Vento; Brian A Darlow; Neena Modi; Franca Rusconi; Stellan Håkansson; Laura San Feliciano; Kjell K Helenius; Dirk Bassler; Shinya Hirano; Shoo K Lee Journal: Transl Pediatr Date: 2019-07
Authors: James V M Hanson; Caroline Weber; Oliver A Pfäffli; Dirk Bassler; Daphne L McCulloch; Christina Gerth-Kahlert Journal: Doc Ophthalmol Date: 2022-10-06 Impact factor: 1.854
Authors: Ryan Swan; Sang Jin Kim; J Peter Campbell; R V Paul Chan; Kemal Sonmez; Kent D Taylor; Xiaohui Li; Yii-Der Ida Chen; Jerome I Rotter; Charles Simmons; Michael F Chiang Journal: Ophthalmol Retina Date: 2018-03-08
Authors: Sam Ebenezer Athikarisamy; Geoffrey Christopher Lam; Stuart Ross; Shripada Cuddapah Rao; Debbie Chiffings; Karen Simmer; Max K Bulsara; Sanjay Patole Journal: BMJ Open Date: 2020-08-05 Impact factor: 2.692